Roquefort Therapeutics (LON:ROQ) Stock Price Down 10.5% – Should You Sell?

Shares of Roquefort Therapeutics plc (LON:ROQ) dropped 10.5% on Wednesday . The stock traded as low as GBX 1.70 ($0.02) and last traded at GBX 1.70 ($0.02). Approximately 19,641,881 shares changed hands during mid-day trading, an increase of 447% from the average daily volume of 3,591,296 shares. The stock had previously closed at GBX 1.90 ($0.02).

Roquefort Therapeutics Stock Up 0.2 %

The stock has a market cap of £2.14 million, a P/E ratio of -1.39 and a beta of 0.05. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The stock’s 50-day moving average is GBX 2.46 and its 200-day moving average is GBX 3.49.

Insider Transactions at Roquefort Therapeutics

In other news, insider Stephen Paul West acquired 400,000 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were bought at an average price of GBX 3 ($0.04) per share, with a total value of £12,000 ($15,535.99). Company insiders own 60.40% of the company’s stock.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.